ArticleThe protein journal2026
Screening of Small Peptide Against Ischemic Fatty-Acid Binding Protein (FABP).
Article in The protein journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A low-molecular-weight cytoplasmic protein called heart-type fatty acid-binding protein (H-FABP) is released by cardiac myocytes during an ischemic episode. The normal serum level of FABP is around 3.5 ± 0.4 ng/ml (males), 3.9 ± 0.4 ng/ml (females), while the cutoff value of H-FABP in case of acute myocardial infarction (AMI) is 21.85 ng/ml within 3 hours. In case of angina pectoris, ischemic patients can be distinguished from non-ischemic patients and treated appropriately by detecting the presence of serum H-FABP in a point-of-care (POC) diagnostic approach. As the mortality rate due to coronary heart disease is on the rise worldwide, serum H-FABP levels can act as a diagnostic marker to assist in the prediction of probable cardiac arrest. In the present work, a small peptide against H-FABP has been screened by phage DNA library screening, which can be used for the development of a rapid and accurate diagnostic system for serum H-FABP. The cloning, expression and purification of the H-FABP protein in bacteria and screening of a 12 amino-acid long screened peptide with moderate affinity for binding to H-FABP is reported. The interaction of the said peptide with H-FABP was confirmed by in-silico methods like molecular docking and molecular dynamics simulation. The affinity of the peptide binding to H-FABP was assessed using Isothermal Titration Calorimetry (ITC). A spontaneous process is indicated by ΔG (-7.98 kcal mol
Indexed as
Identifiers
42213345What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.